C-Myc induced compensated cardiac hypertrophy increases free fatty acid utilization for the citric acid cycle

Journal of Molecular and Cellular Cardiology

Volumn 55, Issue 1, 2013, Pages 156-164

  Olson, Aaron K ^a,b   Ledee, Dolena ^b   Iwamoto, Kate ^b   Kajimoto, Masaki ^b   O'Kelly Priddy, Colleen ^b   Isern, Nancy ^c   Portman, Michael A ^a,b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

^c PACIFIC NORTHWEST NATIONAL LABORATORY   (United States)

Author keywords

Cardiac hypertrophy; Compensated hypertrophy; Fatty acid oxidation; Substrate metabolism

Indexed keywords

ACETOACETIC ACID; FATTY ACID; GLUCOSE; INSULIN; LACTIC ACID; MYC PROTEIN; N ACETYLGLUCOSAMINE; TAMOXIFEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARBON NUCLEAR MAGNETIC RESONANCE; CITRIC ACID CYCLE; CONTROLLED STUDY; ECHOCARDIOGRAPHY; GENE INDUCTION; HEART FUNCTION; HEART HYPERTROPHY; HEART WEIGHT; IMMUNOBLOTTING; ISOLATED HEART; MALE; MORPHOMETRICS; MOUSE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; WESTERN BLOTTING;

ACETYL COENZYME A; ANIMALS; CARDIOMEGALY; CITRIC ACID CYCLE; DISEASE MODELS, ANIMAL; ECHOCARDIOGRAPHY; FATTY ACIDS, NONESTERIFIED; MALE; MICE; MICE, TRANSGENIC; OXIDATION-REDUCTION; OXYGEN CONSUMPTION; PROTEOME; PROTO-ONCOGENE PROTEINS C-MYC;

MUS;

EID: 84872688098     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2012.07.005     Document Type: Article

References (30)

1. Lionetti V., Stanley W.C., Recchia F.A. Modulating fatty acid oxidation in heart failure. Cardiovasc Res May 1 2011, 90(2):202-209.
2. Kolwicz S.C., Tian R. Glucose metabolism and cardiac hypertrophy. Cardiovasc Res May 1 2011, 90(2):194-201.
3. Stanley W.C., Recchia F.A., Lopaschuk G.D. Myocardial substrate metabolism in the normal and failing heart. Physiol Rev Jul 2005, 85(3):1093-1129.
4. Dzimiri N., Al-Bahnasi K., Al-Halees Z. Myocardial hypertrophy is not a prerequisite for changes in early gene expression in left ventricular volume overload. Fundam Clin Pharmacol Feb 2004, 18(1):39-44.
5. Izumo S., Nadal-Ginard B., Mahdavi V. Protooncogene induction and reprogramming of cardiac gene expression produced by pressure overload. Proc Natl Acad Sci U S A Jan 1988, 85(2):339-343.
6. Lee H.G., Chen Q., Wolfram J.A., Richardson S.L., Liner A., Siedlak S.L., et al. Cell cycle re-entry and mitochondrial defects in myc-mediated hypertrophic cardiomyopathy and heart failure. PLoS One 2009, 4(9):e7172.
7. Sadoshima J., Izumo S. Molecular characterization of angiotensin II-induced hypertrophy of cardiac myocytes and hyperplasia of cardiac fibroblasts. Critical role of the AT1 receptor subtype. Circ Res Sep 1993, 73(3):413-423.
8. Starksen N.F., Simpson P.C., Bishopric N., Coughlin S.R., Lee W.M., Escobedo J.A., et al. Cardiac myocyte hypertrophy is associated with c-myc protooncogene expression. Proc Natl Acad Sci U S A Nov 1986, 83(21):8348-8350.
9. Taketani S., Sawa Y., Ichikawa H., Ohtake S., Nishimura M., Kawaguchi N., et al. Change of c-Myc expression and cardiac hypertrophy in patients with aortic valve replacement. Ann Thorac Surg Apr 2001, 71(4):1154-1159.
10. Taketani S., Sawa Y., Taniguchi K., Mitsuno M., Kawaguchi N., Onishi S., et al. C-Myc expression and its role in patients with chronic aortic regurgitation. Circulation Nov 4 1997, 96(9 Suppl.):II-83-II-87. [discussion II-7-9].
11. Xiao G., Mao S., Baumgarten G., Serrano J., Jordan M.C., Roos K.P., et al. Inducible activation of c-Myc in adult myocardium in vivo provokes cardiac myocyte hypertrophy and reactivation of DNA synthesis. Circ Res Dec 7 2001, 89(12):1122-1129.
12. Zhong W., Mao S., Tobis S., Angelis E., Jordan M.C., Roos K.P., et al. Hypertrophic growth in cardiac myocytes is mediated by Myc through a Cyclin D2-dependent pathway. EMBO J Aug 23 2006, 25(16):3869-3879.
13. Dang C.V., O'Donnell K.A., Zeller K.I., Nguyen T., Osthus R.C., Li F. The c-Myc target gene network. Semin Cancer Biol Aug 2006, 16(4):253-264.
14. Ahuja P., Zhao P., Angelis E., Ruan H., Korge P., Olson A., et al. Myc controls transcriptional regulation of cardiac metabolism and mitochondrial biogenesis in response to pathological stress in mice. J Clin Invest May 3 2010, 120(5):1494-1505.
15. Darley-Usmar V.M., Ball L.E., Chatham J.C. Protein O-linked beta-N-acetylglucosamine: a novel effector of cardiomyocyte metabolism and function. J Mol Cell Cardiol Mar 2012, 52(3):538-549.
16. Morrish F., Isern N., Sadilek M., Jeffrey M., Hockenbery D.M. c-Myc activates multiple metabolic networks to generate substrates for cell-cycle entry. Oncogene Jul 9 2009, 28(27):2485-2491.
17. Laczy B., Fulop N., Onay-Besikci A., Des Rosiers C., Chatham J.C. Acute regulation of cardiac metabolism by the hexosamine biosynthesis pathway and protein O-GlcNAcylation. PLoS One 2011, 6(4):e18417.
18. Lunde I.G., Aronsen J.M., Kvaloy H., Qvigstad E., Sjaastad I., Tonnessen T., et al. Cardiac O-GlcNAc signaling is increased in hypertrophy and heart failure. Physiol Genomics Feb 1 2012, 44(2):162-172.
19. Facundo H.T., Brainard R.E., Watson L.J., Ngoh G.A., Hamid T., Prabhu S.D., et al. O-GlcNAc signaling is essential for NFAT-mediated transcriptional reprogramming during cardiomyocyte hypertrophy. Am J Physiol Heart Circ Physiol May 2012, 302(10):H2122-H2130.
20. Hyyti O.M., Olson A.K., Ge M., Ning X.H., Buroker N.E., Chung Y., et al. Cardioselective dominant-negative thyroid hormone receptor (Delta337T) modulates myocardial metabolism and contractile efficiency. Am J Physiol Endocrinol Metab Aug 2008, 295(2):E420-E427.
21. Hyyti O.M., Ledee D., Ning X.H., Ge M., Portman M.A. Aging impairs myocardial fatty acid and ketone oxidation and modifies cardiac functional and metabolic responses to insulin in mice. Am J Physiol Heart Circ Physiol Sep 2010, 299(3):H868-H875.
22. Malloy C.R., Jones J.G., Jeffrey F.M., Jessen M.E., Sherry A.D. Contribution of various substrates to total citric acid cycle flux and anaplerosis as determined by 13C isotopomer analysis and O2 consumption in the heart. MAGMA Mar 1996, 4(1):35-46.
23. Krueger J.J., Ning X.H., Argo B.M., Hyyti O., Portman M.A. Triidothyronine and epinephrine rapidly modify myocardial substrate selection: a (13)C isotopomer analysis. Am J Physiol Endocrinol Metab Nov 2001, 281(5):E983-E990.
24. Lauzier B., Merlen C., Vaillant F., McDuff J., Bouchard B., Beguin P.C., et al. Post-translational modifications, a key process in CD36 function: lessons from the spontaneously hypertensive rat heart. J Mol Cell Cardiol Jul 2011, 51(1):99-108.
25. Finck B.N., Lehman J.J., Leone T.C., Welch M.J., Bennett M.J., Kovacs A., et al. The cardiac phenotype induced by PPARalpha overexpression mimics that caused by diabetes mellitus. J Clin Invest Jan 2002, 109(1):121-130.
26. Belardinelli R., Purcaro A. Effects of trimetazidine on the contractile response of chronically dysfunctional myocardium to low-dose dobutamine in ischaemic cardiomyopathy. Eur Heart J Dec 2001, 22(23):2164-2170.
27. Di Napoli P., Di Giovanni P., Gaeta M.A., D'Apolito G., Barsotti A. Beneficial effects of trimetazidine treatment on exercise tolerance and B-type natriuretic peptide and troponin T plasma levels in patients with stable ischemic cardiomyopathy. Am Heart J Sep 2007, 154(3). [602 e1-5].
28. Fragasso G., Palloshi A., Puccetti P., Silipigni C., Rossodivita A., Pala M., et al. A randomized clinical trial of trimetazidine, a partial free fatty acid oxidation inhibitor, in patients with heart failure. J Am Coll Cardiol Sep 5 2006, 48(5):992-998.
29. Young M.E., Laws F.A., Goodwin G.W., Taegtmeyer H. Reactivation of peroxisome proliferator-activated receptor alpha is associated with contractile dysfunction in hypertrophied rat heart. J Biol Chem Nov 30 2001, 276(48):44390-44395.
30. Conacci-Sorrell M., Ngouenet C., Eisenman R.N. Myc-nick: a cytoplasmic cleavage product of Myc that promotes alpha-tubulin acetylation and cell differentiation. Cell Aug 6 2010, 142(3):480-493.